JEFFREY M SUNDSTROM, M.D.
Osteopathic Medicine at University Dr, Swatara, PA
License number
Pennsylvania 4301100103
Category
Medical Practice
Type
Ophthalmology
License number
Pennsylvania MT193104
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
500 University Dr, Swatara, PA 17033
Phone
(717) 531-8783
Personal information
See more information about JEFFREY M SUNDSTROM at radaris.comName
Address
Phone
Boyertown, PA
394 Townhouse, Hershey, PA 17033
117 Maple Ave, Hershey, PA 17033
101 Townhouse, Hershey, PA 17033
505 E 3Rd St, Boyertown, PA 19512
Professional information
Dr. Jeffrey Sundstrom, Hershey PA - MD (Doctor of Medicine)
Specialties:
Ophthalmology
Address:
500 University Dr, Hershey 17033
(717) 531-8521 (Phone), (717) 531-5009 (Fax)
Ann Arbor Office
1000 Wall St, Ann Arbor 48105
(734) 763-8122 (Phone), (734) 763-1415 (Fax)
1000 Wall St SUITE 710, Ann Arbor 48105
(734) 764-4190 (Phone), (734) 647-8052 (Fax)
RETINA ASSOCIATES PC
2002 Medical Pkwy SUITE 450, Annapolis 21401
(410) 224-6689 (Phone), (410) 224-4620 (Fax)
(717) 531-8521 (Phone), (717) 531-5009 (Fax)
Ann Arbor Office
1000 Wall St, Ann Arbor 48105
(734) 763-8122 (Phone), (734) 763-1415 (Fax)
1000 Wall St SUITE 710, Ann Arbor 48105
(734) 764-4190 (Phone), (734) 647-8052 (Fax)
RETINA ASSOCIATES PC
2002 Medical Pkwy SUITE 450, Annapolis 21401
(410) 224-6689 (Phone), (410) 224-4620 (Fax)
Languages:
English
Hospitals:
500 University Dr, Hershey 17033
1000 Wall St SUITE 710, Ann Arbor 48105
Ann Arbor Office
1000 Wall St, Ann Arbor 48105
RETINA ASSOCIATES PC
2002 Medical Pkwy SUITE 450, Annapolis 21401
Milton S. Hershey Medical Center
500 University Dr, Hershey 17033
1000 Wall St SUITE 710, Ann Arbor 48105
Ann Arbor Office
1000 Wall St, Ann Arbor 48105
RETINA ASSOCIATES PC
2002 Medical Pkwy SUITE 450, Annapolis 21401
Milton S. Hershey Medical Center
500 University Dr, Hershey 17033
Education:
Medical School
Pennsylvania State University / College of Medicine
Graduated: 2003
Pennsylvania State University / College of Medicine
Graduated: 2003
Protein Kinase C Zeta Inhibition To Treat Vascular Permeability
US Patent:
2008002, Jan 24, 2008
Filed:
Jul 23, 2007
Appl. No.:
11/781498
Inventors:
David A. Antonetti - Elizabethtown PA, US
Jeffrey M. Sundstrom - Hershey PA, US
Charles D. Smith - Mount Pleasant SC, US
Jeffrey M. Sundstrom - Hershey PA, US
Charles D. Smith - Mount Pleasant SC, US
Assignee:
The Penn State Research Foundation - University Park PA
International Classification:
A61K 31/381, A61K 31/495, A61K 31/496, C12N 9/99
US Classification:
51425213, 435184, 51425212, 514447
Abstract:
Methods of treating or preventing a disease or disorder in a subject are provided by the present invention which include administering a composition including a therapeutically effective amount of a protein kinase C (PKC) zeta inhibitor. A disease or disorder treated or prevented by administration of a PKC zeta inhibitor is characterized by abnormal vascular permeability. Diseases or disorders treated or prevented by administration of a composition including a therapeutically effective amount of a PKC zeta inhibitor include cancer, an ischemic condition and microvascular complications of a systemic or local condition in the subject, such as diabetes and/or diabetic macular edema. Additionally, methods of inhibiting PKC zeta are provided which include incubating PKC zeta in vivo, in vitro and/or in silico with a PKC zeta inhibitor.
Protein Kinase C Zeta Inhibition To Treat Diabetic Retinopathy
US Patent:
8211893, Jul 3, 2012
Filed:
Aug 18, 2009
Appl. No.:
12/542977
Inventors:
David A. Antonetti - Elizabethtown PA, US
Jeffrey M. Sundstrom - Hershey PA, US
Charles D. Smith - Mount Pleasant SC, US
Jeffrey M. Sundstrom - Hershey PA, US
Charles D. Smith - Mount Pleasant SC, US
Assignee:
The Penn State Research Foundation - University Park PA
International Classification:
A61K 31/497, A61K 31/38
US Classification:
51425213, 514438, 514444
Abstract:
Methods of treating or preventing a disease or disorder in a subject are provided by the present invention which include administering a composition including a therapeutically effective amount of a protein kinase C (PKC) zeta inhibitor. A disease or disorder treated or prevented by administration of a PKC zeta inhibitor is characterized by abnormal vascular permeability. Diseases or disorders treated or prevented by administration of a composition including a therapeutically effective amount of a PKC zeta inhibitor include cancer, an ischemic condition and microvascular complications of a systemic or local condition in the subject, such as diabetes and/or diabetic macular edema. Additionally, methods of inhibiting PKC zeta are provided which include incubating PKC zeta in vivo, in vitro and/or in silico with a PKC zeta inhibitor.